Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and...
NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal
AstraZeneca and Daiichi Sankyo’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 Phase II trial ENHERTU is the first therapy to show... | June 5, 2023
CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023
CHICAGO--(BUSINESS WIRE)--Jun 5, 2023--